Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Tryvio (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Aprocitentan, a dual endothelin receptor antagonist, has shown effectiveness in reducing both seated office and 24-hour ambulatory systolic and diastolic blood pressure levels in patients with resistant hypertension who are already on optimal medical therapy, including at least two to three antihypertensive drugs.
• Aprocitentan significantly reduced systolic and diastolic blood pressure in patients with hypertension at doses of 10 mg and 25 mg. The effectiveness outcomes are reported for the general hypertensive population without further subgroup differentiation.
• Comparative effectiveness details with other antihypertensive drugs, such as non-steroid mineralocorticoid receptor antagonists and selective aldosterone synthase inhibitors, are mentioned, but specific data regarding differences in blood pressure reduction are not provided.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.